200 SIDNEY STREET, CAMBRIDGE, MA
Lease Termination Agreement with BMR-Sidney Research Campus LLC
Stockholders Approve Amendment to 2025 Incentive Award Plan
Investor Presentation
Announces Two Transactions to Strengthen Balance Sheet, Reduce Operating Costs and Extend Projected Operating Cash Runway Well into the First Quarter of 2027
Reports First Quarter 2026 Financial Results and Provides Business Updates
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Executive Appointments - Richard Kender Named Interim CEO at Seres Therapeutics
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
PREM14A